Note: This document contains side effect information about vigabatrin. Some of the dosage forms listed on this page may not apply to the brand name Sabril.
Common side effects of Sabril include: arthralgia, blurred vision, confusion, depression, diplopia, fatigue, weight gain, abnormal gait, ataxia, cough, diarrhea, drowsiness, memory impairment, tremor, irritability, and pharyngolaryngeal pain. Other side effects include: status epilepticus, urinary tract infection, pulmonary congestion, abnormality in thinking, asthenia, depressed mood, dysmenorrhea, erectile dysfunction, eye pain, muscle twitching, paresthesia, peripheral edema, sinus headache, abnormal behavior, abnormal sensory symptoms, anemia, back pain, bronchitis, chest pain, constipation, fever, hypoesthesia, hyporeflexia, lethargy, myalgia, nervousness, nystagmus disorder, peripheral neuropathy, sedated state, toothache, upper abdominal pain, vertigo, malaise, abnormal dreams, bruise, and increased appetite. See below for a comprehensive list of adverse effects.
Applies to vigabatrin: oral powder for solution, oral tablet
Oral route (Powder for Solution; Tablet)
Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases, vigabatrin may also decrease visual acuity.Risk increases with increasing dose and cumulative exposure, but there is no dose or exposure to vigabatrin known to be free of risk of vision loss.Risk of new and worsening vision loss continues as long as vigabatrin is used, and possibly after discontinuing vigabatrin.Baseline and periodic vision assessment is recommended for patients on vigabatrin. However, this assessment cannot always prevent vision damage.Vigabatrin is available only through a restricted program called the Vigabatrin REMS Program. Further information is available at www.vigabatrinREMS.com or 1-866-244-8175.
Along with its needed effects, vigabatrin (the active ingredient contained in Sabril) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking vigabatrin:
Less common or rare
Get emergency help immediately if any of the following symptoms of overdose occur while taking vigabatrin:
Symptoms of overdose
Some side effects of vigabatrin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to vigabatrin: oral powder for reconstitution, oral tablet
The more commonly reported adverse reactions have included headache, somnolence, fatigue, dizziness, weight gain, tremor and visual field defects. This drug can cause permanent vision loss.
Based on adult studies, 30 percent or more of patients can be affected with bilateral concentric visual field constriction ranging in severity from mild to severe. Severe cases may be characterized by tunnel vision to within 10 degrees of visual fixation, which can result in disability. In some cases, damage can occur to the central retina and may decrease visual acuity.
Very common (10% or more): Visual field defect (30% or more), nystagmus (up to 19%), blurred vision (up to 16%), diplopia (up to 16%)
Common (1% to 10%): Asthenopia, eye pain, strabismus, conjunctivitis
Rare (0.01% to 0.1%): Retinal disorder (such as peripheral retinal atrophy)
Very rare (less than 0.01%): Optic neuritis, optic atrophy
Very common (10% or more): Headache (up to 33%), somnolence (up to 26%), dizziness (up to 26%), tremor (up to 16%), memory impairment (up to 16%), abnormal coordination (up to 16%)
Common (1% to 10%): Speech disorder, sensory disturbance, paresthesia, movement disorder (including dystonia, dyskinesia, and hypertonia), either alone or in association with abnormalities in MRI, hyperreflexia, hyporeflexia, hyperesthesia, hypoesthesia, status epilepticus, dysarthria, postical state, sensory loss
Uncommon (0.1% to 1%): Coordination abnormal (ataxia)
Rare (0.01% to 0.1%): Encephalopathy (e.g., sedation, stupor, confusion)
Frequency not reported: Increase in seizure frequency
Postmarketing reports: Dystonia, encephalopathy, hypertonia, hypotonia, muscle spasticity, myoclonus, optic neuritis, dyskinesia
Magnetic Resonance Imaging (MRI) Abnormalities in Infants:
-Abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated with this drug for infantile spasms. Some infants exhibited coincident motor abnormalities, but no causal relationship has been established.
Common (1% to 10%): Acne
Uncommon (0.1% to 1%): Rash
Rare (less than 0.1%): Angioedema, urticaria
Postmarketing reports: Facial edema, angioedema, maculo-papular rash, pruritus, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), alopecia
Very common (10% or more): Excitation (children), agitation (children)
Common (1% to 10%): Agitation, aggression, nervousness, depression, paranoid reaction, irritability, asthenia, fever, thirst, malaise, expressive language disorder, abnormal dreams, mental impairment (thought disturbance), lethargy, disturbance in attention
Uncommon (0.1% to 1%): Hypomania, mania, psychotic disorder
Rare (0.01% to 0.1%): Suicide attempt
Very rare (less than 0.01%): Hallucination
Postmarketing reports: Acute psychosis, apathy, delirium, hypomania, neonatal agitation, psychotic disorder
Very common (10% or more): Weight gain (up to 14%)
Common (1% to 10%): Increased appetite
Very common (10% or more): Fatigue (up to 40%), gait disturbance (up to 12%)
Common (1% to 10%): Edema, tinnitus, vertigo, peripheral edema
Postmarketing reports: Deafness, malignant hyperthermia, multi-organ failure
Common (1% to 10%): Anemia
Postmarketing reports: Birth Defects, delayed puberty, developmental delay
The following birth defects have been reported during the postmarketing period: congenital cardiac defects, congenital external ear anomaly, congenital hemangioma, congenital hydronephrosis, congenital male genital malformation, congenital oral malformation, congenital vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, and talipes.
Very common (10% or more): Diarrhea (up to 16%), nausea (up to 10%)
Common (1% to 10%): Vomiting, abdominal pain, upper abdominal pain, constipation, dyspepsia, stomach discomfort, toothache, abdominal distention, thirst
Postmarketing reports: Gastrointestinal hemorrhage, esophagitis
Common (1% to 10%): Urinary tract infection, dysmenorrhea, erectile dysfunction
Very rare (less than 0.01%): Hepatitis
Frequency not reported: Decreases in ALT and AST
Postmarketing reports: Cholestasis
Very common (10% or more): Arthralgia
Common (1% to 10%): Joint sprain, muscle strain, back pain, pain in extremity, myalgia, muscle twitching, muscle spasms
Very common (10% or more): Upper respiratory tract infection (up to 51%) Nasopharyngitis (up to 14%), pharyngeal pain (up to 14%), cough (up to 14%)
Common (1% to 10%): Bronchitis, pulmonary congestion, sinus headache
Postmarketing reports: Laryngeal edema, pulmonary embolism, respiratory failure, stridor
Common (1% to 10%): Chest pain
Very common (10% or more): Viral infection (up to 20%), pneumonia (up to 13%)
Common (1% to 10%): Influenza
Uncommon (0.1% to 1%): Candidiasis, ear infection, croup infectious
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Sabril (www.drugs.com/sabril.html).
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020